Clinical trial · Observational
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Primären Mammakarzinoms Der Frau Mit Farmorubicin®))
NCT01061359CI-TRIAL-00004240completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg). Evaluation of unexpected and serious adverse events. (E=Epirubicin; C =Cyclophosphamide)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epirubicin: Observational Study | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Non-Interventional Study
- description
- Chemotherapy containing Epirubicin
- interventionNames
- Drug: Epirubicin: Observational Study
Primary outcomes (1)
- measure
- Percentage of Participants With Disease Free Survival (DFS)
- timeFrame
- 3m, 6m, 9m, 1y, 1.5y, 2y, 2.5y, 3y, 3.5y, 4y, 4.5y, 5y
- description
- Percentage of participants with DFS who completed 5 year follow-up visit.
Secondary outcomes (2)
- measure
- Time to Progression (TTP)
- timeFrame
- 3m, 6m, 9m, 1y, 1.5y, 2y, 2.5y, 3y, 3.5y, 4y, 4.5y, 5y
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Pre- and postmenopausal female patients with histologically confirmed primary breast cancer Exclusion Criteria: * Metastatic breast cancer, locally advanced or recurrent breast cancer, previous cancer history
References
Publications (0)
Data not yet available
No reference posted for this study.